No photo of Ben Markman

View Scopus Profile

Ben Markman

Dr

20082024

Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

PACIFIC-Real World: First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (D4194R00005)

Markman, B. & Baker, E.

17/10/19 → 31/12/24

Project: Research

A Phase 1a/1b Multicentre, Open label, Dose escalation and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, And Antitumor Activity of Ak104 in Subjects with Advanced Solid Tumours

Markman, B.

20/09/19 → 19/09/24

Project: Research

A Phase la/lb, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors

Markman, B.

6/06/19 → 5/06/24

Project: Research

An Open-Label, Randomized, Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) study

Markman, B.

3/06/19 → 2/06/24

Project: Research

A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects with Triple Negative Breast Cancer and Colorectal Cancer with Liver Metastases

Markman, B.

20/05/19 → 19/05/24

Project: Research

Research Output

A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Alamgeer, M., Neil Watkins, D., Banakh, I., Kumar, B., Gough, D. J., Markman, B. & Ganju, V., 1 Apr 2018, In : Investigational New Drugs. 36, 2, p. 288-298 11 p.

Research output: Contribution to journal › Article › Research › peer-review

8 Citations (Scopus)

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC

McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., Harris, D. L., Stagg, R. J., Kapoun, A. M., Xu, L. & Hughes, B. G. M., 1 Feb 2018, In : Targeted Oncology. 13, 1, p. 89-98 10 p.

Research output: Contribution to journal › Article › Research › peer-review

13 Citations (Scopus)

mTOR inhibition beyond rapalogs

Markman, B., Serra, V. & Tabernero, J., 2016, mTOR Inhibition for Cancer Therapy: Past, Present and Future. Mita, M., Mita, A. & Rowinsky, E. K. (eds.). Paris France: Springer, p. 251 - 27 25 p.

Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Research › peer-review

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors

Papadopoulos, K. P., Tabernero, J., Markman, B., Patnaik, A., Tolcher, A. W., Baselga, J., Shi, W., Egile, C., Ruiz-Soto, R., Laird, A. D., Miles, D. & LoRusso, P. M., 2014, In : Clinical Cancer Research. 20, 9, p. 2445 - 2456 12 p.

Research output: Contribution to journal › Article › Research › peer-review

Open Access
66 Citations (Scopus)

PI3K pathway inhibitors: better not left alone

Markman, B., Tao, J. J. & Scaltriti, M., 2013, In : Current Pharmaceutical Design. 19, 5, p. 895 - 906 12 p.

Research output: Contribution to journal › Article › Research › peer-review

28 Citations (Scopus)